Boehringer Ingelheim International Gmbh

Hydra Biosciences, Inc.

Evotec International Gmbh

Dirk Gottschling

Klaus Rudolf

Henri Doods

Stephan Georg Mueller

Gerhard Schaenzle

Annekatrin Charlotte Heimann

Dirk Stenkamp

Georg Dahmann

Niklas Heine

Thierry Bouyssou

Joerg P Hehn

Dieter Wiedenmayer

Andreas Blum

Armin Heckel

Michael Robert Turner

Hidenori Takahashi

Hossein Razavi

Christopher Ronald Sarko

Xinyuan Edward Wu

Lana Louise Smith Keenan

Michael Dennis Lowe

Simon Surprenant

Bernhard Schmid

Elke Langkopf

Christoph Hoenke

Doris Riether

Joerg Kley

Kai Gerlach

Thorsten Lehmann-Lintz

Heiner Ebel

Angela Kay Berry

Matthew Russell Netherton

Bernd Wellenzohn

Alexander Dreyer

The present invention relates to compounds of formula (I) wherein A, X, R, R, R, Rand Rare as defined herein, and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, such as hypertension, preeclampsia, restenosis, a cardiac or respiratory condition, renal disease, liver disease, muscular dystrophy, fibrotic disorders, pain, ischemia or ischemic reperfusion injury, and cancer.

Inhibitors of TRPC6

The invention related to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein Rto R, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

The present invention relates to polycyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Rto R, Rto R, Y and A are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. 

The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein Rto R, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

The present invention relates to compounds of general formula I, wherein the group R, X and Y are defined as in claim, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. 

Azabenzimidazole derivatives as agonists of the AMP-activated protein kinase

This invention relates to novel sulfoximine substituted quinazoline derivatives of formula (I), wherein Ar, Rand Rare as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders. 

Sulfoximine substituted quinazolines for pharmaceutical compositions

This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I wherein Ar, Rand Rare as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

This invention relates to novel pyrazolopyrimidines and their use as metabotropic glutamate 5 receptor antagonists (mGlu5 receptor antagonists), pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of mGlu5 receptor mediated disorders.

Pyrazolopyrimidines as metabotropic glutamate 5 receptor antagonists

The present invention relates to the new compounds of general formula I wherein A, U, V, X, Y, R, Rand Rare defined as stated hereinafter, the tautomers, the isomers thereof, the diastereomers, the enantiomers, the hydrates, the mixtures and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.

Pyrimidine derivatives which are CGRP&#x2014;antagonists

This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I wherein Ar, Rand Rare as defined herein, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R, R, Rand Rare defined as mentioned in the description, the tautomers thereof, the isomers thereof, the diastereomers thereof, the enantiomers thereof, the hydrates thereof, the mixtures thereof and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, the use thereof and processes for the preparation thereof.

Compounds

The present invention relates to new CGRP-antagonists of general formula I wherein R, R, R, R, R, R, X, Y and Z are defined as mentioned hereinafter, the individual diastereomers, the individual enantiomers and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, the use thereof and processes for the preparation thereof.

Substituted piperazines as CGRP antagonists

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R, Rand Rare defined as stated hereinafter, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

Growing community of inventors

Mittelbiberach, Germany

Dirk Gottschling